CD19 and acute lymphoblastic leukemia: Shah' team developed new CAR-T cells targeting CD22, which showed encouraging results in B-cell precursor acute lymphoblastic leukemia [42], suggesting that CD22 CAR-T cells may be a joint or remedial therapy for CD19-negative ALL and CD19-negative relapses.